Radius Recycling Inc (OQ:RDUS)

Business Focus: Iron, Steel Mills & Foundries

Apr 16, 2024 09:00 am ET

Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

TYMLOS®demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data

Apr 04, 2024 08:00 am ET

Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results

Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the second quarter of fiscal 2024 ended February 29, 2024. The Company reported a loss per share from continuing operations of $(1.19) and a net loss of $(34) million. Adjusted...

Mar 14, 2024 04:35 pm ET

Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date

Radius Recycling, Inc. (NASDAQ: RDUS) today announced preliminary results for its fiscal 2024 second quarter ended February 29, 2024. Second Quarter Fiscal 2024 Expected Performance The Company anticipates: Net loss to be approximately $(35)...

Mar 04, 2024 08:30 am ET

Radius Recycling Named One of the 2024 World’s Most Ethical Companies

Radius Recycling, Inc. (NASDAQ: RDUS), a global leader in metals recycling, has been recognized as one of the 2024 World’s Most Ethical Companies by Ethisphere, a world leader in defining and advancing the standards of ethical business practices. Radius is among this year’s 136 honorees spannin

Jan 04, 2024 08:00 am ET

Radius Recycling Reports First Quarter Fiscal 2024 Financial Results

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) today reported results for the first quarter of fiscal 2024 ended November 30, 2023.

Dec 18, 2023 09:00 am ET

Radius Recycling Announces First Quarter Fiscal 2024 Earnings Date and Webcast Details

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) announced that the Company will report financial results for its first quarter fiscal 2024 ended November 30, 2023 on Thursday, January 4, 2024. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed on Radius Recycling’s website at

Dec 13, 2023 09:15 am ET

Radius Recycling Publishes Fiscal Year 2023 Sustainability Report

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS), a global leader in metals recycling, today announced the release of the Company’s Fiscal 2023 Sustainability Report, Where Change Begins.

Nov 16, 2023 08:30 am ET

Radius Recycling Executive Included on TIME100 Climate List of the 100 Most Influential Leaders Driving Business Climate Action

Today, TIME named Schnitzer Steel Industries, Inc. dba Radius Recycling’s (NASDAQ: RDUS) Chairman and Chief Executive Officer, Tamara Lundgren, to the inaugural TIME100 Climate List, recognizing the 100 most innovative leaders who are working to advocate for and expedite climate action.

Oct 25, 2023 08:00 am ET

Radius Recycling Reports Fourth Quarter and Fiscal 2023 Financial Results

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) today reported results for the fourth quarter of fiscal 2023 ended August 31, 2023.

Sep 29, 2023 08:30 am ET

Radius Recycling Announces Fourth Quarter and Fiscal 2023 Earnings Date and Webcast Details

Schnitzer Steel Industries, Inc. dba Radius Recycling (NASDAQ: RDUS) announced that the Company will report financial results for its fourth quarter and fiscal 2023 ended August 31, 2023 on Wednesday, October 25, 2023. The Company will host a webcast conference call to discuss the results at 11:30 a.m. Eastern Time on the same day. The webcast of the call and the accompanying slide presentation may be accessed under the Events Calendar on Radius Recycling’s website at

Aug 15, 2022 09:00 am ET

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.

Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) announced today the completion of their acquisition of Radius Health, Inc. (Nasdaq: RDUS) (“Radius”). Radius is a global, commercial-stage biopharmaceutical company...

Aug 11, 2022 06:42 am ET

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancerSubmission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall study population and patients whose tumors harbor an ESR1 mutationU.S. FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of February 17, 2023FLORENCE, Italy and NEW YORK, Aug. 11, 2022 /CNW/ --

Aug 11, 2022 06:42 am ET

Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Jul 14, 2022 02:27 pm ET

SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations

NEW YORK, July 14, 2022 /PRNewswire/ --

Jul 13, 2022 10:50 pm ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, RFP, USAK

Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Radius Health, Inc. (NASDAQ: RDUS)’s...

Jul 13, 2022 12:54 pm ET

RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Radius Health, Inc. (NasdaqGM: RDUS) to Gurnet Point Capital and Patient Square Capital. Under the terms of the proposed transaction, shareholders of Radius will receive only $10.00 per share in cash plus a CVR (Contingent Value Right) of $1.00 per share for each share of Radius that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Compan

Jul 11, 2022 09:00 am ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates DRE, RDUS, FSTX, RADA, USAK

NEW YORK, July 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Jul 11, 2022 08:00 am ET

Velan-Repertoire to Withdraw Director Nominations Due to Pending Sale of Radius Health

Velan Capital Investment Management LP and Repertoire Partners LP (together with the other participants in their solicitation, “Velan-Repertoire” or “we”), collectively one of the largest stockholders of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), with beneficial ownership of approximately 7.7% of the outstanding shares and economic exposure to approximately 10.1% of the outstanding shares, today released the following statement:

Jul 09, 2022 07:13 pm ET

Lifshitz Law PLLC Announces Investigation of FSTX, MBCN, RDUS, and ZEN

F-star Therapeutics, Inc (NASDAQ: FSTX) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of FSTX to invoX Pharma for $7.12 per share. If you are an investor, and would like...

Jul 07, 2022 06:30 pm ET

Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today published a detailed investor presentation available at: https://ir.radiuspharm.com/events-and-presentations/. The document discusses the Company’s progress since 2020 and also...

Jul 07, 2022 08:00 am ET

Radius Announces First Patient Randomized in the RAD011 Pivotal Trial for Prader-Willi Syndrome

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the first patient has been randomized in the Phase 2/3 pivotal study, SCOUT-015, to evaluate RAD011, a synthetic cannabidiol oral solution, for the treatment of...

Jul 06, 2022 11:15 am ET

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ:

Jul 06, 2022 07:22 am ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, TMX, CDEV, MN

Jul 05, 2022 10:34 pm ET

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm

Jun 29, 2022 12:41 am ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HMLP, CTT, RADA, RDUS

Jun 27, 2022 09:10 pm ET

Equity Alert - The M&A Class Action Firm Announces an Investigation of Radius Health, Inc. - RDUS

NEW YORK, June 27, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Radius Health, Inc. (RDUS), relating to its proposed acquisition by Gurnet Point Capital and Patient Square Capital via a tender offer. Under the terms of the agreement, RDUS shareholders will receive $10.00 in cash plus one contingent va

Jun 27, 2022 04:52 pm ET

SHAREHOLDER ALERT: Weiss Law Investigates Radius Health, Inc.

NEW YORK, June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Radius Health, Inc. ("Radius Health" or the "Company") (NASDAQ: RDUS), in connection with the proposed acquisition of the Company by Gurnet Point Capital and Patient Square Capital via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $ 10.00 per share plus a Contingent Value Right (CVR) of $1.00 per share payable upon TYMLOS® net sales reaching $300 million during any consecutive 12-month

Jun 27, 2022 09:00 am ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAK

NEW YORK, June 27, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Jun 24, 2022 08:30 am ET

Velan-Repertoire Comments on Proposed Sale of Radius Health to Gurnet Point Capital and Patient Square Capital

Jun 24, 2022 07:37 am ET

INVESTIGATION NOTICE: Halper Sadeh LLP Investigates USWS, RDUS, FSTX, ADRA

Jun 23, 2022 09:00 pm ET

RADIUS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Radius Health, Inc. - RDUS

Jun 23, 2022 12:50 pm ET

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Radius Health, Inc. (Nasdaq - RDUS), F-star Therapeutics, Inc. (Nasdaq - FSTX), Adara Acquisition Corp. (NYSE A

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...

Jun 23, 2022 12:39 pm ET

Shareholder Alert: Ademi LLP investigates whether Radius Health, Inc. has obtained a Fair Price in its transaction with Gurnet Point and Patient Square

MILWAUKEE, June 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Radius (NASDAQ: RDUS) for possible breaches of fiduciary duty and other violations of law in its transaction with Gurnet Point and Patient Square.

Jun 23, 2022 11:33 am ET

RDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to Shareholders

Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Radius Health, Inc. (NASDAQ: RDUS) to Gurnet Point Capital and Patient Square Capital is fair to Radius Health shareholders. Under the terms of the merger agreement, Gurnet Point and Patient Square will acquire all of the outstanding shares of Radius for $10.00 per share in cash plus a Contingent Value Right of $1.00 per share payable upon TYMLOS® (abaloparatide) net sales reaching $300 million (inclusive of U.S. sales and Japan royalties or supply payments based on supply of TYMLOS for sale in Japan) during an

Jun 23, 2022 09:15 am ET

Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has entered into a definitive agreement to be acquired by Gurnet Point Capital (“Gurnet Point”) and Patient Square Capital (“Patient Square”) in a transaction...

Jun 22, 2022 06:24 pm ET

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022FLORENCE, Italy and BOSTON, June 22, 2022 /CNW/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NASDAQ: RD

Jun 22, 2022 06:24 pm ET

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patientsPriority Review requested; if accepted, anticipate an 8-month FDA reviewPositive EMERALD study data previously announced on October 20, 2021First, and currently only, investigational oral SERD with positive topline resultsAdditional data presented at SABCS (December 2021) and ASCO (June 2022)Plan to file marketing authorization application for elacestrant in the EU in 2H 2022FLORENCE, Italy and BOSTON, June 22, 2022 /PRNewswire/ -- The Menarini Group ("Menarini") and Radius Health, Inc. ("Radius") (NAS

Jun 22, 2022 04:30 pm ET

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) announced that Menarini, with support from Radius, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...

Jun 21, 2022 07:00 am ET

Velan-Repertoire Releases Detailed Presentation on the Need for Board Change at Radius Health and Sends Letter to Stockholders

Jun 16, 2022 09:00 am ET

Rubric Capital Management Sends Letter to Radius Health Board of Directors

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14.62% of the common stock of Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today sent a letter to Radius’ Board of Directors (the “Board”).

Jun 13, 2022 07:00 am ET

Velan-Repertoire Responds to Misleading Characterizations by the Radius Board

Jun 08, 2022 08:00 am ET

Radius Health Expands Non-US Market Footprint for TYMLOS

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection. Radius has entered into agreements with the following companies and markets for...

Jun 07, 2022 07:00 am ET

Velan-Repertoire Group Files Definitive Proxy Materials in Connection With Radius Health 2022 Annual Meeting

Jun 06, 2022 10:54 am ET

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an investigational oral selective estrogen receptor degrader (SERD), vs. investigator's choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC)

Jun 06, 2022 10:54 am ET

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 06, 2022 09:00 am ET

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting of data from the EMERALD...

Jun 06, 2022 07:30 am ET

Radius Files Definitive Proxy and Mails Letter to Stockholders

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has filed its definitive proxy statement with the Securities and Exchange Commission (“SEC”) for its upcoming Annual Meeting of Stockholders, which will be held...

Jun 01, 2022 04:15 pm ET

Radius Health Update on Abaloparatide Transdermal System

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on the abaloparatide transdermal system (abalo-TDS) development program. As previously reported on December 8, 2021, the Phase 3 results for abalo-TDS did not...

May 23, 2022 09:31 am ET

Thinking about buying stock in Radius Health, Humanigen, GoldMining, Porch Group, or BigBear.ai?

NEW YORK, May 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RDUS, HGEN, GLDG, PRCH, and BBAI.

May 20, 2022 09:00 am ET

Radius Adds Industry Veterans Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has added two new independent members to the Board of Directors (the “Board”). Effective immediately, Jennifer A. Jarrett and Susan Vissers Lisa have joined the...

May 20, 2022 03:57 am ET

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

Emerald study met both its primary end points of Progression-free survival (PFS) in overall population and in ESR1 mutated patientsPFS rate at 12 months with elacestrant was 22.32% vs. 9.42% with SOC in the overall population, and 26.76% vs. 8.19% in the ESR1 mutation populationData demonstrated elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutationCompared with fulvestrant, elacestrant demonstrated statistically significant PFS and reduced the risk of progression or death by 32% in the overall population an

May 20, 2022 03:57 am ET

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

May 19, 2022 05:00 pm ET

Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs....

May 05, 2022 07:30 am ET

Radius Health, Inc. First Quarter 2022 Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2022. The Company also provided a general business update. Radius CEO Kelly Martin provided the...

Apr 25, 2022 08:30 am ET

Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that it will release its first quarter 2022 financial results on Thursday, May 5, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to...

Apr 05, 2022 08:00 am ET

Radius Provides Agenda for Today’s R&D Webcast

Today, Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) will host its Neuroscience R&D webcast to discuss RAD011, our investigational synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine,...

Mar 16, 2022 08:30 am ET

Radius Health Announces Leadership Appointments

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS), today announced appointments to new roles on its executive leadership team, effective immediately. Mark Conley has joined Radius as the Company’s Chief Financial Officer. In...

Mar 08, 2022 08:30 am ET

Radius Health Provides Business Update on Bone Health

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided an update on business development and intellectual property progress in its Bone Health franchise. Massachusetts General Hospital Research Collaboration On December 15, 2020,...

Mar 07, 2022 08:30 am ET

Wells Fargo Equity Research to Host Fireside Chat with Radius CEO

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that Kelly Martin, CEO, has accepted an invitation to participate in a virtual fireside chat hosted by Mohit Bansal, Managing Director of Equity Research at Wells Fargo....

Mar 03, 2022 04:05 pm ET

Radius to Host Neuroscience R&D Webcast April 5, 2022

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced details of its virtual R&D Webcast focused on RAD011. RAD011 is the Company’s investigational synthetic cannabidiol oral solution which has potential utilization in...

Mar 01, 2022 08:00 am ET

Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) provided a business progress and regulatory update. On February 25, 2022, the Company filed a Supplemental New Drug Application (sNDA) with the Food and Drug Administration (FDA) for...

Feb 24, 2022 07:30 am ET

Radius Health, Inc. Fourth Quarter & Full Year 2021 Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided key business and financial objectives for 2022. CEO Kelly...

Feb 15, 2022 12:00 pm ET

Radius Health to Release Fourth Quarter and Full Year 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, February 24, 2022

Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to...

Jan 13, 2022 09:00 am ET

Radius Health Completes Business Adjustment

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), has completed an adjustment of its business. The catalyst for the changes was the completion of three pivotal trials during the second half of 2021. Those trial readouts included:...

Dec 23, 2021 08:31 am ET

Thinking about buying stock in Radius Health, Nikola Corp, Ortho Clinical Diagnostics, Energy Focus, or Las Vegas Sands?

NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RDUS, NKLA, OCDX, EFOI, and LVS.

Dec 23, 2021 08:30 am ET

Radius Announces Update on TYMLOS® (abaloparatide) Label

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the TYMLOS label, including the removal of the boxed warning regarding the risk of osteosarcoma....

Dec 20, 2021 08:32 am ET

Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors

Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights’ Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is...

Dec 08, 2021 10:15 am ET

Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio...

Dec 08, 2021 09:00 am ET

Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide...

Dec 08, 2021 09:00 am ET

Radius Health to Host Conference Call Today, Wednesday, December 8, 2021

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below: Discuss topline results from the wearABLe Phase 3 trialReview data...

Nov 11, 2021 08:30 am ET

Radius Health to Participate in the Stifel 2021 Virtual Healthcare Conference

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference, including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021, followed by...

Nov 08, 2021 08:00 am ET

Radius Health, Inc.: Third Quarter 2021 Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its results for the third quarter ended September 30, 2021. Q3, 2021 FINANCIAL HIGHLIGHTS: TYMLOS Net Revenue: $57 million in Q3, 2021 vs. $50 million in Q3, 2020,...

Oct 21, 2021 01:15 pm ET

CORRECTING and REPLACING -- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346)...

Oct 20, 2021 03:00 pm ET

Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021

Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET to discuss the results and...

Oct 20, 2021 10:55 am ET

Thinking about buying stock in Vinco Ventures, Radius Health, FuelCell Energy, BlackBerry, or Peabody Energy?

NEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBIG, RDUS, FCEL, BB, and BTU.

Oct 20, 2021 08:30 am ET

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

the Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced positive topline results from the EMERALD study. The study was designed to evaluate elacestrant as a monotherapy...

Oct 18, 2021 08:30 am ET

Radius Announces Positive Phase 3 Topline Results for TYMLOS® (abaloparatide) Subcutaneous Injection in Males with Osteoporosis

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced positive topline results from the ATOM study evaluating abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The ATOM study met its primary...

Sep 22, 2021 08:00 am ET

TYMLOS Label and Business Update

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), provided a business update. Effective September 20, 2021, the following sentence was added to the MOA section of the TYMLOS (abaloparatide) label: “Once-daily administration of...

Aug 05, 2021 07:00 am ET

Radius Health, Inc.: Second Quarter and Year-to-Date Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the second quarter ended June 30, 2021 and year-to-date. In addition, the Company provided an update on components of the business....

Jul 27, 2021 08:00 am ET

Radius Health Business Update

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), provided a business update today on the Company’s progress. Abaloparatide New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021...

Jul 23, 2021 11:12 am ET

CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

A correction has been issued for a release disseminated under the same headline on July 22nd at 9:00 am EST by Radius Health, Inc. (RDUS), please note that the corrected release contains the revised statement with the typographical correction as...

Jul 22, 2021 09:00 am ET

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a...

Jul 20, 2021 05:10 pm ET

Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021

Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results...

Jun 02, 2021 08:15 am ET

Radius Health Business Update

Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), provided a business update covering continued progress for the Company. Additional business updates will be provided as progress is achieved. ABALOPARATIDE ASSET U.S. TYMLOS...

May 07, 2021 06:30 am ET

Radius Health, Inc.: First Quarter 2021 Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2021. The following are key components of Q1, 2021 performance: Q1, 2021 FINANCIAL HIGHLIGHTS: Total net...

Apr 22, 2021 08:15 am ET

Radius Health Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), provided the following business update. The Company’s first quarter 2021 earnings will take place on Friday, May 7 at 8:30am EST. ABALOPARATIDE ASSET TYMLOS Patient growth increased...

Apr 20, 2021 04:30 pm ET

Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021

Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide...

Mar 24, 2021 08:00 am ET

Radius Health Provides Update on Abaloparatide

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided an update on the abaloparatide asset including regulatory progress as well as U.S. commercial activity. The Company will continue to provide business updates when...

Mar 03, 2021 04:15 pm ET

Radius Health, Inc. Announces $175 Million Financing Transaction

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan,...

Feb 25, 2021 07:00 am ET

Radius Health, Inc.: Fourth Quarter and Full Year Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results. In addition, a number of brief business updates are included. Q4...

Feb 17, 2021 08:30 am ET

Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021. A live webcast of the presentation will be...

Feb 16, 2021 08:30 am ET

Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021

Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results...

Feb 12, 2021 12:33 pm ET

Radius Health, Inc. Provides Abaloparatide Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas. New Patient Growth: TYMLOS in the U.S....

Jan 06, 2021 12:00 pm ET

Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST. A live webcast of the...

Jan 06, 2021 06:00 am ET

Radius Health, Inc. Announces Acquisition of Orphan Disease Program

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics Inc.’s (“Benuvia”) synthetic cannabidiol oral solution...

Jan 05, 2021 08:15 am ET

Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register,...

Jan 05, 2021 07:36 am ET

Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

DUBLIN, Jan. 5, 2021 /CNW/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the agreement, Endo obtained the rights to abaloparatide-subcutaneous injection (abaloparatide-SC) and abaloparatide-transdermal patch (abaloparatide-TD), a novel formulatio

Jan 05, 2021 07:36 am ET

Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc. (NASDAQ: RDUS) to register, commercialize and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc., an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the agreement, Endo obtained the rights to abaloparatide-subcutaneous injection (abaloparatide-SC) and abaloparatide-transdermal patch (abaloparatide-TD), a novel for

Jan 04, 2021 04:30 pm ET

Radius Health Announces Change to its Board of Directors

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company’s board of directors. Ms. Sanders and Dr. von Eschenbach will fill vacancies created by...

Dec 15, 2020 09:00 am ET

Radius Health, Inc. Provides Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020. The key areas of activity and progress are outlined below. Commercial Progress The Company’s focus on...

Nov 05, 2020 08:00 am ET

Radius Health, Inc.: Third Quarter 2020 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2020, and provided a business update. “Over the past few months, we have made reasonable...

Oct 21, 2020 08:15 am ET

Radius Health, Inc.: Progress Since May 2020

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020. The Company will provide further updates during its third quarter earnings call and at subsequent investor...

Oct 20, 2020 04:15 pm ET

Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020

Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and...

Oct 06, 2020 04:30 pm ET

Peter A. Schwartzman Joins Radius Health, Inc.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions (CST) Group. Peter, as part of the group, will...

Oct 01, 2020 08:45 am ET

Radius Health Divests RAD 140 Program to Ellipses Pharma

Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets. Under the agreement,...

Sep 25, 2020 05:51 am ET

Radius Health & Menarini Group Provide Elacestrant Update

WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /CNW/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial.

Sep 24, 2020 04:15 pm ET

Radius Health & Menarini Group Provide Elacestrant Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial. EMERALD Phase 3 Study The target enrollment milestone has been reached in the Phase 3...

Sep 24, 2020 08:15 am ET

Radius Health Provides Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Financial Officer of Radius Health, Inc., with immediate effect. “Pepe joined Radius one month after the FDA...

Sep 09, 2020 07:45 am ET

Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Virtual Meeting which will take place between...

Sep 08, 2020 08:00 am ET

Radius Health: Enrollment Completed for Phase 3 wearABLe trial

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced completion of enrollment in its “wearABLe” phase 3 trial. The study was designed to look at the effects on bone mineral density of abaloparatide delivered via a novel...

Sep 02, 2020 04:15 pm ET

Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management will host virtual meetings with investors during the Citi 15th Annual BioPharma Virtual...

Aug 25, 2020 09:00 am ET

Radius Health Provides Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a business update including the extension of the patent for TYMLOS® as well as the completion of enrollment for its Phase 3 study, which is assessing the safety and...

Aug 10, 2020 08:15 am ET

Radius Health Announces Second Quarter 2020 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update. “Completing the elacestrant transaction was...

Aug 10, 2020 08:15 am ET

Sean Murphy joins Radius Health Board of Directors

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,...

Jul 30, 2020 04:10 pm ET

Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant

Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Radius Health, Inc. (Radius, Nasdaq: RDUS) to pursue regulatory approval of the Guardant360® CDx as a companion diagnostic for elacestrant (RAD1901), an...

Jul 27, 2020 04:15 pm ET

Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020

Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and...

Jul 23, 2020 04:15 pm ET

Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant

The Menarini Group and Radius Health, Inc. (Nasdaq: RDUS) announced today that the companies have entered into an exclusive global license agreement for development and commercialization of elacestrant. Elacestrant is an oral SERD, a selective...

May 27, 2020 05:00 am ET

Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited, has submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at...

May 07, 2020 04:15 pm ET

Radius Health Announces First Quarter 2020 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the first quarter ended March 31, 2020 and provided a business update. “In these challenging and unprecedented times, I am proud...

Apr 28, 2020 04:35 pm ET

Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin, in connection with his appointment as Chief Executive Officer and President of the Company,...

Apr 28, 2020 04:30 pm ET

Radius Health Announces CEO Leadership Transition

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jesper Hoeiland will step down as President and Chief Executive Officer to return, after many years abroad, to his home country of Denmark. In order to assist with...

Apr 20, 2020 04:15 pm ET

Radius Health to Announce First Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday May 7, 2020

Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Thursday, May 7, 2020. The Company will host a conference call and live audio webcast at 4:45 p.m. ET that day to discuss the results and...

Mar 03, 2020 09:15 am ET

Radius Health to Present at Cowen 40th Annual Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the Cowen 40th Annual Healthcare Conference in Boston at 08:40 a.m. ET on Wednesday, March 4, 2020....

Feb 27, 2020 07:30 am ET

Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the fourth quarter and full-year ended December 31, 2019 and provided a business update. “I am very pleased that TYMLOS exited...

Feb 13, 2020 04:05 pm ET

Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020

Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to...

Feb 13, 2020 04:05 pm ET

Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona, CFO will present a corporate update at the 9th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m. ET on Thursday,...

Jan 13, 2020 09:00 am ET

Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that it has exceeded its 2019 financial guidance with unaudited full-year TYMLOS® (abaloparatide) injection U.S. net revenue surpassing the upper range of $172 million....

Jan 06, 2020 04:14 pm ET

Radius Health to Present at the 38th Annual J.P. Morgan Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that its senior executive management team will present a corporate update at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 11:30 am PST at the Westin St....

Dec 06, 2019 09:47 am ET

Radius Health Announces Scientific Presentations at 2019 San Antonio Breast Cancer Symposium (SABCS)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced its scientific presentations on elacestrant and RAD140 at the upcoming 2019 San Antonio Breast Cancer Symposium, which will take place from December 10 – 14 in San...

Dec 02, 2019 04:52 pm ET

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 50,000 shares of the Company’s common stock with a per...

Nov 15, 2019 04:15 pm ET

Radius Health to Present at Jefferies 2019 Global Healthcare Conference in London

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Hoeiland, President and CEO of the Company, will present a corporate update at the Jefferies 2019 Global Healthcare Conference in London, United Kingdom on Wednesday, November 20, 2019...

Nov 05, 2019 04:05 pm ET

Radius Health Announces Third Quarter 2019 Results and Corporate Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2019 and provided a strategic business update. Radius remains confident TYMLOS® will...

Oct 23, 2019 05:37 pm ET

Radius Health to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 5, 2019

Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter 2019 financial results on Tuesday, November 5, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results...

Sep 13, 2019 06:03 pm ET

Radius Health to Present Data on Abaloparatide at ASBMR 2019 Annual Meeting

Radius Health, Inc. (Nasdaq: RDUS), today announced it will present five posters, including results from a real-world study on patient experience, at the American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting, which will take...

Sep 03, 2019 09:00 am ET

Radius Health to Participate in the Citi 14th Annual Biotech Conference and Morgan Stanley 17th Annual Global Healthcare Conference in September

Radius Health, Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2019. Radius Health management will host meetings with investors at the Citi 14th Annual Biotech Conference in Boston on September 5,...

Aug 07, 2019 04:01 pm ET

Radius Health Announces Second Quarter 2019 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2019 and provided a business update. “I am delighted to see continued market share...

Aug 05, 2019 04:00 pm ET

Radius Health Initiates Phase 3 wearABLe Study of Abaloparatide-Patch in Postmenopausal Osteoporosis Patients at High Risk for Fracture

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the randomization of the first patient in the Phase 3 wearABLe clinical trial studying the safety and efficacy of abaloparatide-transdermal patch (abaloparatide-patch)...

Jul 23, 2019 09:00 am ET

Radius Health to Announce Second Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, August 7, 2019

Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter 2019 financial results on Wednesday, August 7th, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the...

Jul 17, 2019 04:52 pm ET

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted a new employee an option to purchase 65,000 shares of the Company’s common stock with a per...

Jun 04, 2019 09:00 am ET

Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona, Chief Financial Officer and Joe Kelly, Senior Vice President of Sales and Marketing, will present a corporate update at the Goldman Sachs 40th Annual Global Healthcare...

May 10, 2019 04:42 pm ET

Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019

May 08, 2019 07:56 am ET

Radius Health Announces First Quarter 2019 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the first quarter ended March 31, 2019 and provided a business update. “I am very pleased to see continued strong market share...

Apr 23, 2019 09:00 am ET

Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019

Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...

Apr 17, 2019 08:00 am ET

Radius Health to Present Two Posters at AACE 2019 Annual Meeting

Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will...

Mar 29, 2019 07:45 am ET

Detailed Research: Economic Perspectives on General Mills, Archrock, Crocs, Monolithic Power, Radius Health, and Gibraltar Industries — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of General Mills, Inc. (NYSE:GIS), Archrock, Inc. (NYSE:AROC), Crocs, Inc....

Mar 23, 2019 12:45 pm ET

Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting

Mar 18, 2019 08:00 am ET

Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting

Mar 11, 2019 04:30 pm ET

Radius Health to Present at Cowen 39th Annual Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39th Annual Healthcare Conference on Wednesday, March 13, 2019. Information on the presentation...

Mar 01, 2019 09:00 am ET

Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with...

Feb 28, 2019 04:05 pm ET

Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the fourth quarter and full-year ended December 31, 2018 and provided a business update. “I am very pleased with the continued...

Feb 19, 2019 09:00 am ET

Radius Health to Present at Leerink Partners 8th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Leerink Partners 8th Annual Global Healthcare Conference on Friday, March 1, 2019. Information on the...

Feb 14, 2019 09:00 am ET

Radius Health to Announce Fourth Quarter and Full Year 2018 Financial Results, Host Conference Call and Live Webcast on Thursday, February 28, 2019

Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to...

Feb 06, 2019 07:45 am ET

Detailed Research: Economic Perspectives on Edwards Lifesciences, Zimmer Biomet, American Outdoor Brands, Radius Health, Kaman, and FARO Technologies — What Drives Growth in Today's Competitive Landsc

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Edwards Lifesciences Corporation (NYSE:EW), Zimmer Biomet Holdings, Inc....

Jan 25, 2019 09:00 am ET

Radius Health Appoints Jessica Hopfield, Ph.D., to Board of Directors

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and...

Jan 07, 2019 09:22 am ET

Radius Exceeds 2018 Financial Guidance and Provides Business Update at the 37th Annual J.P. Morgan Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales surpassing the upper range of $95 to $98 million. Radius closed 2018 with a $235 million cash, cash...

Jan 02, 2019 04:15 pm ET

Radius Health to Present at the 37th Annual J.P. Morgan Healthcare Conference

Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 1:30 pm PST at the...

Dec 06, 2018 08:00 am ET

LogicBio Therapeutics Appoints Richard Moscicki, M.D., and Michael Wyzga to Board of Directors

LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment biopharmaceutical industry leaders Richard Moscicki, M.D. and Michael Wyzga to its...

Nov 30, 2018 09:00 am ET

Radius Health Provides Updates on its Oncology Programs and Announces Scientific Presentations at 2018 San Antonio Breast Cancer Symposium (SABCS)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced updates from its oncology pipeline and its scientific presentations on elacestrant and RAD140 at the upcoming 2018 San Antonio Breast Cancer Symposium. The Company’s...

Nov 07, 2018 07:25 am ET

Recent Analysis Shows InterDigital, Alpha and Omega Semiconductor, Alliance Resource Partners, Aircastle, XPO Logistics, and Radius Health Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of InterDigital, Inc. (NASDAQ:IDCC), Alpha and Omega Semiconductor Limited...

Nov 01, 2018 07:40 am ET

Radius Health Announces Third Quarter 2018 Operating Results and Financial Guidance for FY 2018 and FY 2019

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today reported its financial and operating results for the third quarter ended September 30, 2018 and provided a business update. “I am very pleased with the continued strong...

Oct 12, 2018 09:00 am ET

Radius Health to Announce Third Quarter 2018 Financial Results, Host Conference Call and Live Webcast on November 1, 2018

Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...

Oct 09, 2018 08:25 am ET

Report: Exploring Fundamental Drivers Behind Skyworks Solutions, Radius Health, Novanta, Flowers Foods, Rexford Industrial Realty, and Donaldson — New Horizons, Emerging Trends, and Upcoming Developme

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Skyworks Solutions, Inc. (NASDAQ:SWKS), Radius Health, Inc....

Oct 03, 2018 07:52 am ET

Radius Health Announces Latest 2019 Medicare Part D Coverage for TYMLOS® (abaloparatide) Injection

Sep 28, 2018 08:30 am ET

Radius Health to Present at the Leerink Partners Oncology Roundtable Series

Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris, Chief Medical Officer of the Company will present a corporate update at the Leerink Partners Oncology Roundtable Series on Wednesday,...

Sep 24, 2018 08:00 am ET

Radius Health to Present Data on Abaloparatide at ASBMR 2018 Annual Meeting

Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it will present...

Sep 11, 2018 09:15 am ET

Radius Health to Present at the Morgan Stanley 16th Annual Global Health Care Conference

Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO, and Pepe Carmona, Chief Financial Officer of the Company, will present a corporate update at the Morgan Stanley 16th Annual Global Health Care Conference on...

Sep 06, 2018 04:15 pm ET

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors granted Dr. Charles Morris, in connection with his appointment as the Company’s Chief Medical Officer, an option to purchase 130,000...

Sep 04, 2018 09:15 am ET

Radius Health Appoints Dr. Charles Morris as Chief Medical Officer

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced the appointment of Dr. Charles Morris as Chief Medical Officer. Dr. Morris will oversee and lead all clinical development, regulatory and medical affairs strategies and...

Sep 04, 2018 08:00 am ET

BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations

BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the...

Aug 07, 2018 07:45 am ET

Radius Health Reports Second Quarter 2018 Financial and Operating Results and Provides Business Update

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the second quarter ended June 30, 2018 and provided a business update. “We are very pleased to report our continued progress in increasing...

Aug 01, 2018 07:30 am ET

New Research Coverage Highlights Ladder Capital, Gibraltar Industries, Norwegian Cruise Line, Wolverine World Wide, Catalyst Pharmaceuticals, and Radius Health — Consolidated Revenues, Company Growth,

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ladder Capital Corp (NYSE:LADR), Gibraltar Industries, Inc. (NASDAQ:ROCK),...

Jul 24, 2018 04:15 pm ET

Radius Health Provides Update on Appeal of CHMP Opinion for Abaloparatide-SC

Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that...

Jul 23, 2018 04:44 pm ET

Radius Health to Announce Second Quarter 2018 Financial Results, Host Conference Call and Live Webcast on August 7, 2018

Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter financial results on Tuesday, August 7, 2018. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and...

Jul 16, 2018 07:28 pm ET

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Compensation Committee of the Company’s Board of Directors granted Chhaya Shah, in connection with her appointment as the Company’s Senior Vice President,...

Jul 16, 2018 08:00 am ET

Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations. "Ms. Shah will help strengthen and expand our technical operations infrastructure,...

Jun 07, 2018 08:30 am ET

Radius Health to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the at the Goldman...

Jun 05, 2018 08:30 am ET

Radius to Host Investor Day on June 8, 2018

Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host an Investor Day on Friday, June 8, 2018 in New York City starting at 8:00 a.m. ET. Members of the Radius leadership team will provide business updates and facilitate discussions...

May 11, 2018 08:09 pm ET

Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference

Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will present a corporate update at the Bank of America...

May 10, 2018 07:30 am ET

Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS), today reported its financial results for the first quarter ended March 31, 2018 and provided a business update. “The Company’s first quarter results highlight the strong...

Apr 24, 2018 08:00 am ET

Radius Health to Announce First Quarter 2018 Financial Results, Host Conference Call and Live Webcast on May 10, 2018

WALTHAM, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter financial results on Thursday, May 10, 2018. The Company will host a conference call and live audio webcast...

Apr 20, 2018 08:10 am ET

Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health — Future Expectations, Projections Moving into 2018

NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clean Energy Fuels Corp. (NASDAQ:CLNE), Catalyst...

Mar 30, 2018 02:32 pm ET

Radius Health Initiates Phase 3 Clinical Trial of Abaloparatide Injection for the Treatment of Male Osteoporosis

Bridging study will evaluate change in spine bone mineral density (BMD) at 12 months compared with placebo

Mar 22, 2018 09:00 am ET

Radius Health Provides Update on CHMP Opinion for Abaloparatide-SC

WALTHAM, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced that...

Mar 17, 2018 12:30 pm ET

Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection at ENDO 2018 Annual Meeting

WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today presented results...

Mar 12, 2018 04:30 pm ET

Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection

WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced two presentations...

Mar 06, 2018 08:01 am ET

Radius Health to Present at the Cowen 38th Annual Health Care Conference

WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at Cowen’s 38th Annual Health Care Conference on Monday, March...

Mar 01, 2018 04:01 pm ET

Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update

TYMLOS™ sales show accelerating market share growth, capturing approximately 32% of osteoporosis patients new to anabolic therapy

Feb 14, 2018 08:00 am ET

Radius Health to Announce Fourth Quarter and Full Year 2017 Financial Results, Host Conference Call and Live Webcast on March 1, 2018

WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018. The Company will host a conference...

Feb 14, 2018 08:00 am ET

Radius Health to Present at 2018 RBC Capital Markets Global Healthcare Conference

WALTHAM, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and CEO of the Company, will present a corporate update at the 2018 RBC Capital Markets Global Healthcare Conference on...

Feb 14, 2018 07:45 am ET

Analysis: Positioning to Benefit within First Data, Target, Kellogg, Builders FirstSource, HD Supply, and Radius Health — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, Feb. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC), Target Corporation...

Feb 08, 2018 08:00 am ET

Radius Health to Present at Leerink Partners 7th Annual Global Healthcare Conference

WALTHAM, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced...

Jan 05, 2018 09:07 am ET

Radius Health to Present at the 36th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January...

Jan 02, 2018 08:05 am ET

Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications

WALTHAM, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) announced today that Elhan Webb has joined the Company as Head of Investor Relations and External Communications.

Dec 15, 2017 07:31 am ET

Radius Health Announces that the Committee for Medicinal Products for Human Use (CHMP) Will Issue a Third Day-180 List of Outstanding Issues in its Regulatory Review of Abaloparatide-SC, a Bone Buildi

Radius Health now anticipates an opinion from the CHMP regarding the MAA for abaloparatide-SC in the first half of 2018

Dec 11, 2017 01:30 pm ET

Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl Award at...

Dec 07, 2017 06:30 pm ET

Radius Investigational Drug Elacestrant (RAD1901) Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

-Elacestrant 400mg single agent Objective Response Rate (ORR) was 27.3% in heavily pre-treated patients with advanced ER+ breast cancer at the pre-determined study cutoff date of October 30, 2017-

Dec 04, 2017 09:05 am ET

Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)

SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer

Nov 30, 2017 08:00 am ET

New Research: Key Drivers of Growth for First Data, Target, Kellogg, Builders FirstSource, HD Supply, and Radius Health — Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of First Data Corporation (NYSE:FDC), Target Corporation...

Nov 27, 2017 04:35 pm ET

Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that its Board of Directors granted Joseph Kelly, in connection with his appointment as the Company’s Senior Vice President of...

Nov 27, 2017 04:05 pm ET

Radius Health Announces Commercial Leadership Changes with Appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and Promotion of Amanda Mott to Senior Vice President of Market

WALTHAM, Mass., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Joseph Kelly as Senior Vice President of Sales and Marketing, and the promotion of Amanda Mott to...

You are here

Radius Recycling Inc (OQ:RDUS)

Business Focus: Iron, Steel Mills & Foundries